ISSN: 2347-6567

International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR)

IJAMSCR | Vol.15 | Issue 4| Jan - Mar -2026

www.ijamscr.com

DOI : https://doi.org/10.61096/ijamscr.v14.iss1.2026.303-308

# Pharmacological Challenges in Triple-Negative Breast Cancer Therapy

**Shaktiprasad Pradhan[1*], Pradyumna Kumar Behera[2], Ankita Moharana[3], Swetaparna S. Pradhan[4]**

[1]*Department of Pharmaceutical Chemistry, Koustuv Research Institute of Medical Science, Koustuv Technical Campus, Bhubaneswar, Odisha, India*

[2]*Department of CM & FM, AIIMS, Bhubaneswar, Odisha, India*

[3]*Department of Pharmacology, Koustuv Research Institute of Medical Science, Koustuv Technical Campus, Bhubaneswar, Odisha, India*

[4]*Mother's School & College of Nursing, Bhubaneswar, Odisha, India*

* Corresponding author: shakti.pharma16@gmail.com

Published by: 17.03.2026



**Abstract:** Triple-negative breast cancer (TNBC) represents one of the most therapeutically challenging breast cancer subtypes owing to the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. This molecular profile eliminates the utility of conventional endocrine and HER2-targeted therapies, leaving systemic chemotherapy as the historical backbone of treatment. However, high intratumoral heterogeneity, early metastatic dissemination, adaptive drug resistance, and substantial treatment-related toxicity continue to compromise durable clinical benefit. Advances in molecular profiling have revealed actionable vulnerabilities including DNA damage repair defects, immune checkpoint susceptibility, and dysregulated growth factor signaling, enabling the emergence of poly (ADP-ribose) polymerase inhibitors, immune checkpoint inhibitors, and antibody–drug conjugates. Despite these advances, variable biomarker predictability, resistance evolution, and limited access to precision diagnostics constrain optimal patient stratification. Pharmacokinetic challenges such as poor tumor penetration, dose-limiting toxicities, and interpatient variability further complicate therapeutic optimization. This review critically examines the pharmacological barriers in TNBC therapy, integrating mechanistic insights into tumor biology, resistance pathways, immunomodulation, and emerging targeted platforms. Key clinical trial evidence and translational strategies aimed at overcoming therapeutic resistance are highlighted. The synthesis underscores the necessity of integrated biomarker-driven treatment algorithms, rational drug combinations, and innovative delivery technologies to improve survival outcomes and minimize systemic toxicity in TNBC patients.

**Keywords**: Triple-negative breast cancer; Drug resistance; Immunotherapy; Targeted therapy; Pharmacokinetics

## Introduction

Triple-negative breast cancer accounts for approximately 15–20% of all breast malignancies and is characterized by aggressive biological behavior, high proliferative index, and early metastatic potential [1]. The absence of hormone receptors and HER2 amplification eliminates the benefit of endocrine therapy and HER2-targeted agents, thereby restricting systemic management primarily to cytotoxic chemotherapy [2]. Although initial chemo sensitivity is often observed, relapse rates remain

high and long-term survival remains inferior compared with hormone receptor–positive subtypes [3].

Molecular profiling has revealed extensive genomic instability in TNBC, frequently involving defects in DNA repair pathways, particularly BRCA1 and BRCA2 mutations, which provide therapeutic vulnerability to poly (ADP-ribose) polymerase (PARP) inhibitors [4]. Parallel advances in tumor immunology have demonstrated increased tumor-infiltrating lymphocytes and programmed death-ligand 1 expression in subsets of TNBC, enabling the clinical application of immune checkpoint inhibitors [5]. Antibody–drug conjugates targeting surface antigens such as Trop-2 have further expanded the therapeutic armamentarium [6]. Despite these innovations, clinical outcomes remain heterogeneous due to intertemporal diversity, dynamic resistance mechanisms, and incomplete biomarker predictability [7].

Pharmacological challenges extend beyond target availability to encompass drug delivery limitations, unfavourable pharmacokinetics, overlapping toxicities, and drug–drug interactions during combination therapy [8]. Moreover, socioeconomic disparities and limited access to molecular diagnostics in many healthcare systems hinder equitable implementation of precision oncology [9]. A comprehensive understanding of these multifactorial challenges is essential to refine therapeutic strategies and optimize patient outcomes.

This review systematically analyzes the pharmacological barriers encountered in TNBC therapy, emphasizing molecular heterogeneity, resistance biology, immunotherapeutic limitations, targeted drug development constraints, and translational opportunities for personalized medicine [10].

**1. Molecular Heterogeneity and Therapeutic Target Limitations**

TNBC is not a single molecular entity but comprises multiple biologically distinct subtypes including basal-like, mesenchymal, immunomodulatory, and luminal androgen receptor phenotypes [11]. This heterogeneity drives differential drug sensitivity and complicates uniform treatment algorithms. Basal-like tumors exhibit heightened genomic instability and DNA repair deficiencies, whereas mesenchymal tumours display enhanced epithelial–mesenchymal transition and chemo resistance [12]. Such diversity limits the predictive accuracy of single biomarkers and increases therapeutic failure rates.

Target scarcity remains a fundamental pharmacological barrier. Unlike hormone receptor–positive breast cancer, TNBC lacks consistent receptor-driven targets amenable to long-term suppression [13]. Emerging targets such as androgen receptor, PI3K/AKT/mTOR signalling components, and growth factor receptors demonstrate variable expression across patient cohorts, reducing broad applicability [14]. Additionally, tumor plasticity allows dynamic switching between molecular states under therapeutic pressure, further eroding treatment durability [15].

Intratumoral heterogeneity also influences drug penetration and micro environmental interactions, affecting pharmacodynamics efficacy [16]. Hypoxic niches and stromal barriers impede uniform drug distribution, creating sub clonal sanctuaries that promote resistance emergence. These biological complexities necessitate multi-targeted approaches and adaptive treatment strategies rather than single-agent interventions [17].

**Table 1.** Molecular subtypes of TNBC and therapeutic implications

| Subtype | Dominant Features | Potential Targets | Therapeutic Challenges |
|---|---|---|---|
| Basal-like | DNA repair defects, high proliferation | PARP, platinum agents | Resistance development |
| Mesenchymal | EMT, stromal interaction | PI3K/AKT inhibitors | Drug penetration limits |
| Immunomodulatory | Immune infiltration | PD-1/PD-L1 inhibitors | Immune escape |
| Luminal AR | Androgen receptor signaling | AR antagonists | Variable expression |

## 2. Chemo resistance Mechanisms and Pharmacodynamics Barriers

Chemotherapy remains foundational in TNBC management, yet intrinsic and acquired resistance significantly limit durable responses [18]. Overexpression of drug efflux transporters such as P-glycoprotein reduces intracellular drug accumulation, diminishing cytotoxic efficacy [19]. Enhanced DNA damage repair pathways and apoptosis evasion further attenuate chemotherapeutic sensitivity.

Cancer stem-like cells within TNBC exhibit quiescent phenotypes and heightened detoxification capacity, enabling survival following cytotoxic exposure [20]. These subpopulations drive relapse and metastatic dissemination. Tumor micro environmental factors including hypoxia and inflammatory cytokines modulate drug response by altering cellular metabolism and signalling pathways [21].

Pharmacodynamics variability arises from interpatient differences in drug metabolism, hepatic clearance, and transporter polymorphisms [22]. Dose intensification is often constrained by cumulative toxicity, particularly myelosuppression and neuropathy. Combination regimens may improve efficacy but increase adverse event burden and limit adherence. Strategies incorporating sequential scheduling, metronomic dosing, and Nano carrier delivery systems aim to enhance therapeutic index and reduce systemic toxicity [23].

## 3. Immunotherapeutic Challenges and Tumor Immune Evasion

Immune checkpoint inhibitors have demonstrated meaningful benefit in PD-L1–positive metastatic TNBC; however, response rates remain modest [24]. Primary resistance arises from low neoantigen burden, impaired antigen presentation, and immunosuppressive tumor microenvironments dominated by regulatory T cells and myeloid-derived suppressor cells [25].

Adaptive immune escape mechanisms include upregulation of alternative checkpoint molecules, cytokine-mediated T-cell exhaustion, and loss of interferon signalling [26]. Pharmacokinetic limitations of monoclonal antibodies, including limited tumor penetration and long systemic exposure, contribute to immune-related adverse events affecting endocrine and gastrointestinal systems.

Biomarker inconsistency further complicates patient selection. PD-L1 assays exhibit variability across platforms, and tumor mutational burden lacks standardized thresholds [27]. Combination immunotherapy strategies integrating chemotherapy, radiotherapy, or targeted agents aim to enhance immunogenic cell death and immune priming. However, overlapping toxicities and unpredictable synergistic effects require cautious optimization through translational modelling and adaptive trial designs [28].




**Figure 1:** Schematic representation of immune escape mechanisms in TNBC and therapeutic intervention points.

## 4. Targeted Therapies and Antibody–Drug Conjugates

PARP inhibitors have demonstrated efficacy in germline BRCA-mutated TNBC, yet resistance emerges via restoration of homologous recombination repair and drug efflux upregulation [29]. PI3K/AKT inhibitors offer benefit in pathway-activated tumors but are limited by metabolic toxicities and compensatory signalling activation [30].

Antibody–drug conjugates (ADCs) such as sacituzumab govitecan deliver cytotoxic payloads selectively to tumor cells expressing Trop-2, improving response rates in heavily pre-treated patients [31]. Nevertheless, heterogeneity of antigen expression, payload-associated toxicity, and complex manufacturing processes restrict scalability and cost-effectiveness [32].

Drug stability, linker cleavage kinetics, and off-target accumulation influence ADC pharmacokinetics and safety profiles. Rational optimization of linker chemistry and payload selection remains essential to enhance therapeutic window. Future ADC platforms integrating bispecific targeting and immune-stimulating payloads may improve selectivity and durability of response [33].

**Table 2.** Key targeted therapies and pharmacological considerations in TNBC

| Agent Class | Example | Target | Key Limitation |
|---|---|---|---|
| PARP inhibitors | Olaparib | DNA repair | Resistance |
| Immune checkpoint inhibitors | Pembrolizumab | PD-1 | Immune toxicity |
| ADCs | Sacituzumab govitecan | Trop-2 | Cost, toxicity |
| PI3K inhibitors | Alpelisib | PI3K pathway | Metabolic effects |

## 5. Pharmacokinetic Variability and Toxicity Management

Interindividual variability in drug absorption, metabolism, and elimination significantly influences TNBC treatment outcomes [34]. Genetic polymorphisms in cytochrome P450 enzymes alter systemic exposure, impacting both efficacy and toxicity. Renal and hepatic impairment further complicate dose optimization in elderly or comorbid populations.

Cumulative toxicities such as cardiotoxicity, neuropathy, and immunotoxicity limit prolonged therapy [35]. Polypharmacy increases risk of drug–drug interactions, particularly in combination regimens incorporating targeted agents and immunotherapies. Therapeutic drug monitoring and population pharmacokinetic modelling offer potential strategies to personalize dosing and mitigate adverse events [36].

Advanced drug delivery systems including liposomal formulations and nanoparticle carriers enhance tumor accumulation while reducing systemic exposure [37]. Integration of digital health monitoring and real-time biomarker feedback may further optimize therapeutic adaptation and adherence.

## 6. Translational Innovations and Precision Oncology Integration

Multi-omics profiling enables comprehensive characterization of TNBC molecular landscapes, facilitating biomarker-driven therapy selection [38]. Liquid biopsy technologies permit real-time monitoring of resistance evolution and minimal residual disease, enabling adaptive treatment modification [39].

Artificial intelligence–driven predictive modelling integrates genomic, imaging, and clinical datasets to optimize therapeutic sequencing and toxicity prediction [40]. Patient-derived organoids and xenograft platforms allow functional drug screening, enhancing translational relevance and reducing empirical treatment selection [41].

Regulatory challenges, cost constraints, and limited infrastructure in low-resource settings impede widespread adoption of precision oncology frameworks. Collaborative data-sharing initiatives and standardized biomarker validation are essential to ensure reproducibility and equitable access [42]. Continued integration of translational science with clinical trial innovation will be critical to overcome pharmacological barriers in TNBC therapy.




**Figure 2:** Integrated precision oncology workflow for TNBC incorporating multi-omics profiling and adaptive therapy selection.

## Conclusion

Triple-negative breast cancer continues to pose substantial pharmacological challenges due to molecular heterogeneity, limited target availability, evolving resistance mechanisms, and complex pharmacokinetic variability. While advancements in immunotherapy, PARP inhibition, and antibody–drug conjugates have expanded therapeutic options, durable clinical benefit remains inconsistent across patient populations. The interplay between tumor biology, micro environmental dynamics, and systemic drug disposition necessitates a multidimensional therapeutic framework rather than isolated target-centric approaches. Integration of biomarker-driven stratification, real-time resistance monitoring, and innovative delivery technologies offers a path toward improving therapeutic precision and minimizing toxicity. Translational platforms such as organoid modelling and artificial intelligence–guided analytics further enhance individualized treatment planning. Future progress depends on harmonizing clinical trial design with mechanistic insights, strengthening access to molecular diagnostics, and fostering interdisciplinary collaboration. A sustained commitment to precision pharmacology will be essential to transform TNBC from a therapeutically refractory disease into a manageable clinical entity.

## References

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938–48. doi: 10.1056/NEJMra1001389.
2. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer. Nat Rev Clin Oncol. 2016; 13(11):674–90. doi:10.1038/nrclinonc.2016.66.
3. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15):4429–34. doi:10.1158/1078-0432.CCR-06-3045.
4. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017; 377(6):523–33. doi:10.1056/NEJMoa1706450.
5. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced TNBC. N Engl J Med. 2018; 379(22):2108–21. doi: 10.1056/NEJMoa1809615.
6. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic TNBC. N Engl J Med. 2021; 384(16):1529–41. doi:10.1056/NEJMoa2028485.
7. Lehmann BD, Bauer JA, Chen X, et al. Identification of human TNBC subtypes. J

Clin Invest. 2011; 121(7):2750–67. doi: 10.1172/JCI45014.
8. Blanchard Z, Paul BT, Craft B, ElShamy WM. BRCA1 and DNA repair. Breast Cancer Res. 2015; 17:115. doi:10.1186/s13058-015-0633-9.
9. Prager GW, Braga S, By tricky B, et al. Global disparities in oncology care. ESMO Open. 2018; 3(6):e000400. doi: 10.1136/ esmoopen-2018-000400.
10. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy in TNBC. N Engl J Med. 2020; 382(9):810–21. doi: 10.1056/NEJMoa1910549.
11. Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis of TNBC. Nature. 2015; 520(7547):243–48. doi: 10.1038/nature14393.
12. Creighton CJ. The molecular profile of TNBC. Breast Cancer Res. 2012; 14(3):R89. doi: 10.1186/bcr3194.
13. Shah SP, Roth A, Goya R, et al. Mutational evolution in breast cancer. Nature. 2012; 486(7403):395–99. doi: 10.1038/nature10933.
14. Lehmann BD, Pietenpol JA. Identification of TNBC subtypes. Clin Cancer Res. 2014; 20(24):6379–87. doi:10.1158/1078-0432.CCR-14-1231.
15. Turner NC, Reis-Filho JS. Genetic heterogeneity in cancer. Lancet Oncol. 2012; 13(4):e178–85. doi: 10.1016/S1470-2045(12)70031-8.
16. Jain RK. Transport of molecules in the tumor interstitial. Cancer Res. 1987; 47(12):3039–51. doi:10.1158/0008-5472.CAN-87-0039.
17. Baselga J, Swain SM. Novel anticancer targets. Nat Rev Cancer. 2009; 9(7):463–77. doi:10.1038/nrc2656.
18. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance. Nat Rev Cancer. 2013; 13(10):714–26. doi: 10.1038/nrc3599.
19. Gottesman MM, Lavi O, Hall MD, Gillet JP. Toward a better understanding of MDR. Nat Rev Cancer. 2016; 16(4):221–34. doi:10.1038/nrc.2016.11.
20. Phi LTH, Sari IN, Yang YG, et al. Cancer stem cells. Stem Cells Int. 2018; 2018:5416923. doi:10.1155/2018/5416923.
21. Quail DF, Joyce JA. Micro environmental regulation of tumor progression. Nat Med. 2013; 19(11):1423–37. doi:10.1038/nm.3394.
22. Wilkinson GR. Drug metabolism variability. N Engl J Med. 2005; 352(21):2211–21. doi:10.1056/NEJMra032424.
23. Torchilin VP. Multifunctional Nano carriers. Nat Rev Drug Discov. 2014; 13(11):813–27. doi: 10.1038/nrd4333.
24. Emens LA, Cruz C, Eder JP, et al. PD-1 blockade in TNBC. J Clin Oncol. 2015; 33(9):983–90. doi:10.1200/JCO.2014.57.8325.
25. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells. Nat Immunol. 2013; 14(10):1014–22. doi:10.1038/ni.2703.